Pfizer lays out MRSA vaccine battle plan

May 23, 2013 | By
Tools

Reuters has looked inside the Pfizer ($PFE) lab tasked with developing a vaccine for the drug-resistant superbug MRSA. Merck ($MRK) flunked late phase trials in 2011, but a host of drugmakers are still in the race. Pfizer thinks its multipronged approach can stop the bacterium. Feature

Filed Under
, , superbugs

Comments

Press Releases
  • Abbott Announces New $3 Billion Share Repurchase Program, Declares Dividend
  • Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
  • CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
  • Cempra Provides Guidance on the Clinical Program Required for Regulatory Approval for Solithromycin for Community-Acquired Bacterial Pneumonia (CABP)
  • Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China
  • More Press Releases
Featured Jobs
  • Customer Service/Collection Representative
    Twiline Productions - New York NY America
  • Director of Biologics
    Bristol-Myers Squibb - Syracuse, NY
  • Manager, (Solid Tumor) - Commercial Training Job
    Celgene Corporation - Summit NJ US
  • Clinical Project Manager
    aTyr Pharma -
  • Senior Manager / Associate Director, IT Business Partner, Technical Operations Job
    Celgene Corporation - Berkeley Heights NJ US